Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

812.11 +12.54 (+1.57%)
Streaming Delayed Price Updated: 3:17 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims
The FDA finds Eli Lilly's video on Zepbound and Mounjaro misleading, citing omissions of serious risks. 
Via Benzinga
Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing
Eli Lilly plans a $5 billion Virginia facility to expand drug production, create 650 jobs, and use advanced tech for cancer and autoimmune treatments. 
Via Benzinga
Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside
Via Stocktwits
Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment
Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients. 
Via Benzinga
3 Undervalued Healthcare Stocks to Buy Now While They're Cheap
In an otherwise hot stock market, healthcare stocks are underperforming. 
Via The Motley Fool
Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report
Via Stocktwits
Google DeepMind Chief Eyes Radical AI-Powered Shift In Drug Discovery Speed — Eli Lilly, Novartis Are Already Onboard
Via Stocktwits
Forecasting The Future: 10 Analyst Projections For Eli Lilly
 
Via Benzinga
3 Great High-Yield Dividend Stocks to Buy in September
Quality yields above 6% from three very different market sectors. 
Via The Motley Fool
Here Is My Top Stock Pick Among the Weight Loss Industry Leaders
The weight loss drug market may reach $95 billion within five years. 
Via The Motley Fool
Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition
Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance.... 
Via MarketMinute
Topics Economy Intellectual Property
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows. 
Via Benzinga
Topics Government
Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook
Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor... 
Via MarketMinute
Why Novo Nordisk Stock Popped Today
A price cut could help get Novo Nordisk stock back in the race against Eli Lilly. 
Via The Motley Fool
1 Stock That Should Be in Every Investor's Portfolio
Eli Lilly has seen weakness in its stock price year to date. I think it's a short-term problem. 
Via The Motley Fool
3 Monster Stocks to Hold for the Next 5 Years
They could deliver market-beating returns beyond 2030. 
Via The Motley Fool
Topics Artificial Intelligence
2 Beaten-Down Stocks to Buy and Hold Forever
Their prospects look intact despite some recent roadblocks. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
This Vanguard ETF Makes It Easy to Invest in the "Magnificent Seven"
The "Magnificent Seven" stocks have done incredibly well over the past five years, with six of them more than doubling in value during that time frame. 
Via The Motley Fool
Topics ETFs
3 No-Brainer Dividend Stocks to Buy in September
The attraction of these dividend stocks isn't limited to their dividends. 
Via The Motley Fool
Topics Intellectual Property
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
Eli Lilly Loses Appeal Over Medicaid Drug Pricing Fraud Case
A U.S. appeals court upheld a $183.7 million judgment against Eli Lilly in a whistleblower case, finding the company misreported drug prices and shorted Medicaid rebates. 
Via Benzinga
Topics Fraud Whistleblower
Here's How Much $100 Invested In Eli Lilly 15 Years Ago Would Be Worth Today
 
Via Benzinga
This Under-the-Radar Healthcare Stock Could Soar in 2026
We should know a lot more by year-end. 
Via The Motley Fool
1 Super Stock Down More Than 20% to Buy Hand Over Fist, According to Wall Street
The positives for this big drugmaker appear to outweigh the negatives. 
Via The Motley Fool
Topics Earnings Government World Trade
Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio
The Vanguard Growth ETF provides concentrated exposure to the market's most innovative giants and has a proven history of strong, long-term returns. 
Via MarketBeat
Topics Artificial Intelligence ETFs Economy
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback
One of them is already a leader in the market for weight management drugs, and the other could join this field. 
Via The Motley Fool
Topics ETFs
Novo Nordisk’s “Employee Diet” Trims Workforce By 9,000
Via AB Newswire
Topics Economy Workforce
Why Eli Lilly's Stock Could Be Gearing Up for a Big Rally
Lilly could launch its GLP-1 pill by this time next year. 
Via The Motley Fool
2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades
A decade from now, you could regret ignoring these no-brainer stock picks. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.